GT Biopharma (GTBP)
NASDAQ:GTBP
Want to see GTBP full AI Analyst Report?
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.26 - $3.85
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.63M
Market Cap
$16.12M
Enterprise Value-$3.84M
Total Cash (Recent Filing)$8.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding36,062,904
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetZero reported debt materially reduces solvency risk for a pre-revenue biotech. A debt-free balance sheet preserves strategic flexibility to fund trials or restructure financing, lowering fixed obligations and improving resilience against liquidity shocks over the next several quarters.
Academic-sponsored Phase 1a/1b Trial For GTB-5550A university-sponsored IND and investigator-initiated trial shifts regulatory and operational burden, provides external scientific validation, and limits direct clinical infrastructure costs. This partnership can accelerate clinical proof-of-concept while containing near-term spend and reputational risk.
Governance Change To Lower Meeting QuorumReducing quorum requirements lowers the risk of adjourned meetings and repeated solicitations, enabling more reliable vote outcomes for financing or corporate actions. Improved governance efficiency can materially reduce operational delays and legal/administrative costs over time.
Bears Say
Pre-revenue And Widening Net LossesSustained pre-revenue status with growing net losses constrains the firm's ability to self-fund development. Continued negative earnings erode equity cushions, increase reliance on external capital, and raise dilution risk while prolonging uncertainty about commercial viability.
Consistent Negative Operating Cash FlowPersistent negative operating and free cash flow indicate ongoing cash burn to support R&D and trials. Without meaningful revenue, the company must access capital markets repeatedly, which can limit strategic choices, delay programs if financing tightens, and pressure long-term sustainability.
Volatile Equity And Elevated Funding RiskVolatile equity and prior negative shareholders' equity underscore capital fragility. Coupled with recurring losses, this elevates funding and continuity risk: the firm may need frequent financing rounds, increasing dilution and potentially constraining R&D timelines and strategic independence.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.26 and its highest was $3.85 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $16.12M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Aug 12, 2026 which is in 58 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on May 18, 2026. The company reported -$0.11 earnings per share for the quarter, the consensus estimate of -$0.11 by $0.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.08.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 36,062,904 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$0.11 in its last earnings report, expectations of -$0.11. Following the earnings report the stock price went down -7.379%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
2.37%
Insiders
1.33% Mutual Funds
0.67% Other Institutional Investors
94.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---